These findings have demonstrated the oncogenic functions of AGAP2-AS1 in NSCLC, gastric cancer, and breast cancer, where the involvement of epigenetic proteins like EZH2, LSD1, and CREB-binding protein (CBP) enables it to effectively suppress the transcription of downstream targets. This evidence concerns the gene AGAP2 and breast cancer.